EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 235 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Neighborhood Celebrates Teen’s Last Chemo Session With Socially-Distanced Parade March 27, 2020 Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions July 1, 2020 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... March 23, 2021 Load more HOT NEWS Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... Coping with COVID: New Stimulus Funds and Unemployment Benefit Update Mylan Recalls Injectable Cancer Drug After Particulates Discovered Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated...
